Meyka Pro banner
Jazz Pharmaceuticals plc

Stay Updated with the Latest Jazz Pharmaceuticals plc JAZZ News in Real Time

Find JAZZ news now at Meyka AI. Stay informed with the latest Jazz Pharmaceuticals plc stocks updates, including price news, market analysis, and expert insights.

JAZZ●NASDAQ
HealthcareBiotechnology
$231.39
$4.65(1.97%)
U.S. Market opens in 11h 26m
Shell Greenlights $33B LNG Canada Phase 2, Doubling Export Capacity to 28 Mtpa
📅 6 days ago

Shell Greenlights $33B LNG Canada Phase 2, Doubling Export Capacity to 28 Mtpa

Shell approves $33 billion LNG Canada Phase 2 expansion on September 29, doubling facility capacity to 28 mtpa by early 2030s. Meyka grades SHEL as A-rated Buy with 12-month forecast at $91.95.

Read more 12
US Trade Deficit Hits $88.6B in July as AI Chip Imports Surge
📅 1 month ago

US Trade Deficit Hits $88.6B in July as AI Chip Imports Surge

US trade deficit reached $88.6 billion in July 2026, up 24% from June. AI-driven demand for semiconductors and computers pushed imports to record highs while exports fell 2.1%.

Read more 12
Netflix’s Raygun Documentary Drops September 1: Breaking Badly Tells Her Side
📅 1 month ago

Netflix’s Raygun Documentary Drops September 1: Breaking Badly Tells Her Side

Netflix’s Untold: Raygun Breaking Badly premiered September 1, 2026. The documentary follows Australian breakdancer Rachael Gunn’s controversial 2024 Paris Olympics routine and addresses cheating allegations that spread online.

Read more 12
Air Canada Faces Crisis as FAA Fires Controllers Over LaGuardia Crash Negligence
📅 1 month ago

Air Canada Faces Crisis as FAA Fires Controllers Over LaGuardia Crash Negligence

FAA fires LaGuardia air traffic controllers who left early before deadly Air Canada crash. Two pilots killed in March 22 collision. Staffing crisis deepens.

Read more 12
AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial
📅 1 month ago

AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial

AstraZeneca said Thursday its drug Tezspire met all primary and secondary goals in a late-stage trial. The Phase III CROSSING trial tested Tezspire against placebo in eosinophilic oesophagitis (EoE). AstraZeneca developed the drug jointly with Amgen for this chronic inflammatory oesophagus condition. What the CROSSING Trial Showed The Phase III CROSSING trial evaluated two once-every-four-week…

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
📅 2 months ago

Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update

Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.

Read more 12
AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit
📅 2 months ago

AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit

AstraZeneca has halted a late-stage trial of its lung cancer drug Volrustomig, marking a fresh pipeline setback. The FTSE 100 company said the drug, combined with chemotherapy, was unlikely to improve survival rates. An Independent Data Monitoring Committee recommended stopping the Phase 3 trial after a planned review.  This marks AstraZeneca’s second major trial halt…

Read more 12
2,500 Organizations Hit by LiteLLM Supply Chain Attack in March
📅 2 months ago

2,500 Organizations Hit by LiteLLM Supply Chain Attack in March

LiteLLM supply chain attack in March 2026 exposed 2,500+ organizations and 434,000 CI/CD pipelines. Malicious code ran for 40 minutes, stealing AWS, GCP, and Azure credentials from major tech companies.

Read more 12
Kennedy Center Ordered to Pay $250,000 to Jazz Musician Chuck Redd, August 11
📅 2 months ago

Kennedy Center Ordered to Pay $250,000 to Jazz Musician Chuck Redd, August 11

Judge Tanya Jones Bosier ordered the Kennedy Center to pay $252,479.70 in legal fees to Chuck Redd after dismissing a breach of contract lawsuit. Redd canceled his annual Christmas Eve performance in December 2025 to protest Trump’s name being added to the arts center.

Read more 12

JAZZ News FAQ